Although macrophage-based anti-tumor strategies so far have mainly focused on the inhibition of TAM recruitment (16), another novel immunotherapeutic strategy has recently shown success: the blockade of the “don’t eat me” pathway CD47/SIRPα. This evidence concerns the gene CD47 and neoplasm.